Cargando…

Targets of autoantibodies in acquired hemophilia A are not restricted to factor VIII: data from the GTH-AH 01/2010 study

The root cause of autoantibody formation against factor VIII (FVIII) in acquired hemophilia A (AHA) remains unclear. We aimed to assess whether AHA is exclusively associated with autoantibodies toward FVIII or whether patients also produce increased levels of autoantibodies against other targets. A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oleshko, Olga, Werwitzke, Sonja, Klingberg, Annika, Witte, Torsten, Eichler, Hermann, Klamroth, Robert, Holstein, Katharina, Hart, Christina, Pfrepper, Christian, Knöbl, Paul, Greil, Richard, Neumeister, Peter, Reipert, Birgit M., Tiede, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2022
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830154/ https://www.ncbi.nlm.nih.gov/pubmed/35947142 http://dx.doi.org/10.1182/bloodadvances.2022008071

Ejemplares similares

von Willebrand factor modulates immune complexes and the recall response against factor VIII in a murine hemophilia A model
por: Oleshko, Olga, et al.
Publicado: (2023)

Factor VIII activity and bleeding risk during prophylaxis for severe hemophilia A: a population pharmacokinetic model
por: Tiede, Andreas, et al.
Publicado: (2020)

Abstracts of the 35th annual meeting of the GTH
Publicado: (1991)

Dexamethasone promotes durable factor VIII-specific tolerance in hemophilia A mice via thymic mechanisms
por: Georgescu, Maria T., et al.
Publicado: (2018)

GEROFIT TO HOME (GTH) AS A NEW MODEL OF CARE
por: Harris, Rebekah, et al.
Publicado: (2022)

Somatostatin, as a Bridge Between the GH-Axis and the Gth-Axis
por: Mizrahi, Naama, et al.
Publicado: (2021)

Prevention and Management of Bleeding Episodes in Patients with Acquired Hemophilia A
por: Knöbl, Paul
Publicado: (2018)

Comparative analysis of marketed factor VIII products: reply
por: Reipert, B. M., et al.
Publicado: (2018)

Postpartum Acquired Hemophilia Factor VIII Inhibitors and Response to Therapy
por: Karakuş, Volkan, et al.
Publicado: (2012)

Idiopathic Acquired Hemophilia A with Undetectable Factor VIII Inhibitor
por: Abt, Nicholas B., et al.
Publicado: (2014)

The factor VIII treatment history of non‐severe hemophilia A
por: Abdi, Amal, et al.
Publicado: (2020)

40th Annual Meeting of the GTH (Gesellschaft für Thrombose- und Hämostaseforschung)
Publicado: (1996)

Indirect Treatment Comparison of Damoctocog Alfa Pegol versus Turoctocog Alfa Pegol as Prophylactic Treatment in Patients with Hemophilia A
por: Vashi, Parth, et al.
Publicado: (2021)

Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A
por: Sherman, Alexandra, et al.
Publicado: (2017)

Hemophilia and von Willebrand disease: Factor VIII and von Willebrand factor
por: Sharma, Prashant
Publicado: (2019)

Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies for Hemophilia A Patients
por: Khalilian, Sheyda, et al.
Publicado: (2020)

Pathological mechanism and antisense oligonucleotide-mediated rescue of a non-coding variant suppressing factor 9 RNA biogenesis leading to hemophilia B
por: Krooss, Simon, et al.
Publicado: (2020)

Correction: Pathological mechanism and antisense oligonucleotide-mediated rescue of a non-coding variant suppressing factor 9 RNA biogenesis leading to hemophilia B
por: Krooss, Simon, et al.
Publicado: (2021)

Matching-adjusted indirect comparisons of annualized bleeding rate and utilization of BAY 94-9027 versus three recombinant factor VIII agents for prophylaxis in patients with severe hemophilia A
por: Batt, Katharine, et al.
Publicado: (2019)

The Patient Experience of Gene Therapy for Hemophilia: Qualitative Interviews with Trial Patients
por: Miesbach, Wolfgang, et al.
Publicado: (2020)

Safety of intramuscular COVID‐19 vaccination in patients with haemophilia
por: Tiede, Andreas, et al.
Publicado: (2022)

Recombinant factor VIII in the management of hemophilia A: current use and future promise
por: Powell, Jerry S
Publicado: (2009)

Characterization of anti-factor VIII antibody in a patient with acquired hemophilia A
por: Oh, Jisu, et al.
Publicado: (2013)

Potential role of a new PEGylated recombinant factor VIII for hemophilia A
por: Wynn, Tung Thanh, et al.
Publicado: (2016)

Clot stability as a determinant of effective factor VIII replacement in hemophilia A
por: Leong, Lilley, et al.
Publicado: (2017)

Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?
por: Lieuw, Kenneth
Publicado: (2017)

Factor VIII Intron 22 Inversion in Severe Hemophilia A Patients in Palestine
por: Mahmoud Abu Arra, Caesar, et al.
Publicado: (2020)

Treatment of Hemophilia A Using Factor VIII Messenger RNA Lipid Nanoparticles
por: Chen, Chun-Yu, et al.
Publicado: (2020)

Factor VIII and Factor IX Activity Measurements for Hemophilia Diagnosis and Related Treatments
por: Bowyer, Annette E., et al.
Publicado: (2022)

Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A
por: Bukkems, Laura H., et al.
Publicado: (2022)

Abstracts of the 37th annual meeting of the GTH (Gesellschaft für Thrombose- und Hämostase-forschung)
Publicado: (1993)

The prevalence of factor VIII and IX inhibitors among Saudi patients with hemophilia: Results from the Saudi national hemophilia screening program
por: Owaidah, Tarek, et al.
Publicado: (2017)

Safety and efficacy of long‐term emicizumab prophylaxis in hemophilia A with factor VIII inhibitors: A phase 3b, multicenter, single‐arm study (STASEY)
por: Jiménez‐Yuste, Víctor, et al.
Publicado: (2022)

Serum TNF-α, GTH and MDA of high-fat diet-induced obesity and obesity resistant rats
por: Wu, Peixian, et al.
Publicado: (2016)

Systematic sequence engineering enhances the induction strength of the glucose-regulated GTH1 promoter of Komagataella phaffii
por: Flores-Villegas, Mirelle, et al.
Publicado: (2023)

Hemophilia A gene therapy via intraosseous delivery of factor VIII-lentiviral vectors
por: Miao, Carol H.
Publicado: (2016)

Novel Severe Hemophilia A Mouse Model with Factor VIII Intron 22 Inversion
por: Han, Jeong Pil, et al.
Publicado: (2021)

B cell–activating factor modulates the factor VIII immune response in hemophilia A
por: Doshi, Bhavya S., et al.
Publicado: (2021)

Bispecific antibodies mimicking factor VIII in hemophilia A: converting innovation to an essential medicine
por: Hermans, Cedric, et al.
Publicado: (2023)

Factor VIII inhibitors in hemophilia A treated with emicizumab: longitudinal follow-up of outcomes
por: Levy-Mendelovich, Sarina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a38f8ps2tb8oks60hvim89p1nd